Although there are many newer agents that can be used to treat metastatic melanoma and renal cell carcinoma, it is our practice that IL-2 should be offered in the first or second line of therapy for patients who have normal baseline cardiopulmonary status with the goal of achieving durable regressions. This evidence concerns the gene IL2 and metastatic melanoma.